Prestige Consumer Healthcare Inc. (PBH) vs Xeris Biopharma Holdings, Inc. (XERS)
- Prestige Consumer Healthcare Inc. PBH 49.92 +1.46%
- Xeris Biopharma Holdings, Inc. XERS 10.28 +2.09%
Prestige Consumer Healthcare Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Prestige Consumer Healthcare Inc. is the larger, with a market value of $2.3B against $1.8B — 1.3× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Prestige Consumer Healthcare Inc. trades at 13.9×. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 36.3% against −1.36%. Prestige Consumer Healthcare Inc. has the higher net margin (15.6% vs −5.12%) and the lower return on invested capital (4.70% vs 18.9%). Across the 20 metrics below, Prestige Consumer Healthcare Inc. leads on 12 and Xeris Biopharma Holdings, Inc. on 8.
Valuation
Profitability
| Metric | PBH | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 53.53% | 86.58% | 53.94% |
| Operating margin | 26.26% | 10.91% | 0.00% |
| Net margin | 15.57% | (5.12%) | 0.00% |
| Free cash flow margin | 21.30% | 16.60% | 0.00% |
| Return on equity | 9.12% | 118.22% | (0.40%) |
| Return on assets | 4.30% | (4.60%) | (3.32%) |
| Return on invested capital | 4.70% | 18.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack